Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZhong ZhengSCShu ChengWZWei Zhao

Discussion

Loading...

Member takes

Overview

Phase II trial shows 89.3% overall response rate in treatment-naïve high-risk follicular lymphoma, suggesting new therapeutic approaches.

Key Points

  • To evaluate the efficacy and safety of obinutuzumab, lenalidomide, and zanubrutinib in high-risk follicular lymphoma.
  • Single-arm phase II trial
  • Enrolled treatment-naïve adults with high-risk follicular lymphoma
  • Induction therapy included obinutuzumab, lenalidomide, and zanubrutinib for six cycles
  • Primary endpoint was overall response rate after induction
  • Maintenance therapy included obinutuzumab and lenalidomide.
  • 30 patients enrolled, median age 57 years
  • Overall response rate was 89.3% (25/28) among response-evaluable patients
  • Complete response rate was 67.8% (19/28)
  • No treatment discontinuations for safety reasons
  • Further exploration of therapeutic mechanism is planned.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d714https://doi.org/10.1182/blood-2025-7123
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  2. 2Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  3. 3Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  4. 4Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  5. 5Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma2025